According to the study, vorinostat attacks the enzymes that keep HIV hiding in certain CD4+ Tcells. These are the cells that HIV uses to replicate. Within hours of being given vorinostat, six clinical trial patients had a significant increase in HIV RNA in these cells. The study's author, professor of medicine, microbiology and immunology, and epidemiology Dr.David Margolis, says this is evidence that the virus was being forced out of its hiding. The results were presented March 8 at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle, Washington.
More study is needed, but if the drug proves viable it could shed light on HIV's resting place. Once there, science can turn from defense to offense and work to eradicate the virus completely.”